Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v3-FR | Version v2-EN |
|---|---|---|
| Language | French (Updated) | English |
| Date Updated | 2026-04-17 | 2026-04-17 |
| Drug Identification Number | 02496364 | 02496364 |
| Brand name | XOFLUZA | XOFLUZA |
| Common or Proper name | Baloxivir Marboxil | Baloxivir Marboxil |
| Company Name | HOFFMANN-LA ROCHE LIMITED | HOFFMANN-LA ROCHE LIMITED |
| Ingredients | BALOXAVIR MARBOXIL | BALOXAVIR MARBOXIL |
| Strength(s) | 20MG | 20MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL | ORAL |
| Packaging size | 2 x 20mg Tablets | 2 x 20mg Tablets |
| Anatomical Therapeutical Chemical (ATC) code | J05AX | J05AX |
| Anatomical Therapeutical Chemical (ATC) description | ||
| Reason for shortage | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated start date | 2026-04-20 | 2026-04-20 |
| Actual start date | 2026-04-20 | 2026-04-20 |
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Due to changes in the production of Xofluza, the 40mg strength is changing formulations. The 2x20mg tablets (DIN# 02496364) have a direct replacement for patients of the 1x40mg tablets (DIN# 02496372). There will be no patient impact by switching the formulation to 1x40mg tablets (DIN# 02496372). All wholesalers and distributors will be made aware of this change in formulation. | Due to changes in the production of Xofluza, the 40mg strength is changing formulations. The 2x20mg tablets (DIN# 02496364) have a direct replacement for patients of the 1x40mg tablets (DIN# 02496372). There will be no patient impact by switching the formulation to 1x40mg tablets (DIN# 02496372). All wholesalers and distributors will be made aware of this change in formulation. |
| Health Canada comments |